Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056195 | 1.00 | APLNR (0.40) | APLNRCA1CA2CA4 | |
| SCHEMBL11508353 | 0.82 | APLNR (0.50) | APLNR | |
| SCHEMBL16434721 | 0.76 | CA1 (0.33) | CA1CA2CA4 | |
| SCHEMBL8416856 | 0.76 | ALDH1A1 (0.46) | CA1CA2CA4 | |
| SCHEMBL11582392 | 0.71 | APLNR (0.40) | APLNR | |
| SCHEMBL21406329 | 0.71 | APLNR (0.43) | APLNRCA1CA2CA4 | |
| SCHEMBL13311922 | 0.70 | APLNR (0.42) | APLNRCA1CA2CA4 | |
| SCHEMBL11582155 | 0.70 | APLNR (0.39) | APLNR | |
| SCHEMBL11584123 | 0.70 | APLNR (0.39) | APLNR | |
| SCHEMBL13310980 | 0.70 | APLNR (0.42) | APLNRCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096929-A1 | Novel Use | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096929-A1 | Novel Use | MPO, EPX, XDH | APLNR 3397/4885CA1 1074/4885CA2 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.